Product nameAnti-MIP-3 beta/CCL19 antibody (Biotin)
See all MIP-3 beta/CCL19 primary antibodies
DescriptionRabbit polyclonal to MIP-3 beta/CCL19 (Biotin)
Tested applicationsSuitable for: WB, ELISAmore details
Species reactivityReacts with: Human
- WB: Recombinant human MIP-3 beta/CCL19.
FormLyophilised:Reconstitute in sterile PBS with 0.1% BSA to 0.1 - 1.0 mg/ml.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.20
Constituents: PBS, 0.1% BSA
Concentration information loading...
Our Abpromise guarantee covers the use of ab271285 in the following tested applications.
|WB||Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 11 kDa.
When used in conjunction with compatible secondary reagents, the detection limit for recombinant Human MIP-3 beta/CCL19 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
|ELISA||Use a concentration of 0.25 - 1 µg/ml.
Using ab271285 in conjunction with an appropriate capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant human MIP-3 beta/CCL19.
FunctionMay play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Specifically binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes.
Tissue specificityExpressed at high levels in the lymph nodes, thymus and appendix. Intermediate levels seen in colon and trachea, while low levels found in spleen, small intestine, lung, kidney and stomach.
Sequence similaritiesBelongs to the intercrine beta (chemokine CC) family.
- Information by UniProt
- Beta chemokine exodus 3 antibody
- Beta-chemokine exodus-3 antibody
- C C chemokine ligand 19 antibody
Lane 1: Marker.
Lane 2: Recombinant hMIP-3 beta/CCL19 at 250ng/lane.
Lane 3: Recombinant hMIP-3 beta/CCL19 at 125ng/lane.
Lane 4: Recombinant hMIP-3 beta/CCL19 at 62.5ng/lane.
Lane 5: Recombinant hMIP-3 beta/CCL19 at 31.25ng/lane.
Lane 6: Recombinant hMIP-3 beta/CCL19 at 15.625ng/lane.
Lane 7: Recombinant hMIP-3 beta/CCL19 at 7.8ng/lane.
Lane 8: Recombinant hMIP-3 beta/CCL19 at 3.9ng/lane.
Lane 9: Recombinant hMIP-3 beta/CCL19 at 1.95ng/lane.
Lane 10: Recombinant hMIP-3 beta/CCL19 at 0.975ng/lane.
Lane 11: Recombinant hMIP-3 beta/CCL19 at 0.4875ng/lane.
Lane 12: Recombinant hMIP-3 beta/CCL19 at 0.24ng/lane.
Human MIP-3 beta/CCL19 was detected by sandwich ELISA (using 100μl/well) using a concentration of 0.25-1.0 μg/ml of ab271285. This antibody in conjunction with an appropriate capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant MIP-3 beta/CCL19 protein.
ab271285 has not yet been referenced specifically in any publications.